查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1435471

2024 年寡核苷酸治疗全球市场报告

Oligonucleotide Therapy Global Market Report 2024
出版日期: 按订单生产 | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

寡核苷酸治疗市场规模预计在未来几年将快速成长。预计到 2028 年将以 11.8% 的复合年增长率 (CAGR) 增长至 87.5 亿美元。预测期的延长可归因于研发投资的增加、全球市场渗透、治疗领域的扩大、疾病改善策略和监管适应。预测期内的主要趋势包括个人化治疗、递送系统的进步、 RNA干扰（RNAi）的创新、反义寡核苷酸的进步以及基因编辑技术的整合。

预计全球癌症病例的增加将有助于预测期内寡核苷酸治疗市场的成长。例如，截至 2022 年 1 月，美国癌症协会报告称，美国约有 190 万例新诊断癌症和 609,360 例癌症相关死亡，平均每天约有 1,670 例死亡。肺癌、摄护腺癌和肠癌是全球最常见的癌症类型，而女性乳癌占所有新癌症病例的 43%。因此，全球癌症发生率的快速增加预计将增加未来几年对寡核苷酸治疗市场的需求。

旨在医学研究和开发的政府措施预计将推动寡核苷酸治疗市场的成长。这些措施涉及各级政府（地方、区域、国家或国际）解决具体问题、实现既定目标或促进社会积极变革。它包括当局采取的具体行动、计划、政策或计划。各政府机构已经推出了支持寡核苷酸治疗等各方面的医疗倡议。据英国卫生和社会保障部称，英国政府已承诺在 2022 年提供 2.6 亿英镑（2.7065 亿美元）资金用于加强医学研究和製造。该资金由 BEIS 和 DHSC 提供，旨在透过新的隐私保护平台和临床研究服务来支持 NHS主导的诊断​​和治疗健康研究。也拨款 6,000 万英镑（6,360 万美元）用于支持英国生命科学製造业的扩张。

目录

第一章执行摘要

第二章 市场特点

第三章 市场趋势与策略

第四章宏观经济情景

  • 高通膨对市场的影响
  • 乌克兰与俄罗斯战争对市场的影响
  • COVID-19 对市场的影响

第五章世界市场规模与成长

  • 全球寡核苷酸治疗市场的驱动与限制因素
    • 市场驱动因素
    • 市场限制因素
  • 2018-2023年全球寡核苷酸治疗市场规模表现与成长
  • 2023-2028、2033年全球寡核苷酸治疗市场规模及成长预测

第六章市场区隔

  • 全球寡核苷酸治疗市场，按类型、实际和预测细分，2018-2023、2023-2028、2033
  • 反义寡核苷酸
  • 适体
  • 其他的
  • 全球寡核苷酸治疗市场，按应用、效能和预测细分，2018-2023、2023-2028、2033
  • 感染疾病
  • 瘤
  • 神经退化性疾病
  • 心血管疾病
  • 肾臟疾病
  • 其他的
  • 全球寡核苷酸治疗市场，按最终用户细分，实际和预测，2018-2023、2023-2028、2033
  • 医院
  • 研究机构

第 7 章 区域与国家分析

  • 全球寡核苷酸治疗市场，按地区、绩效及预测，2018-2023、2023-2028、2033
  • 全球寡核苷酸治疗市场，依国家、绩效及预测，2018-2023、2023-2028、2033

第八章亚太市场

第九章 中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第14章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章 义大利市场

第20章 西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章加拿大市场

第26章 南美洲市场

第27章 巴西市场

第28章 中东市场

第29章 非洲市场

第三十章 竞争形势及公司概况

  • 寡核苷酸治疗市场竞争形势
  • 寡核苷酸治疗市场公司概况
    • Pfizer Inc.
    • Merck &Co. Inc.
    • GlaxoSmithKline plc
    • Gelead Sciences Inc.
    • BioNTech SE

第31章 其他大型创新公司

  • Moderna Inc.
  • Biogen Inc.
  • Bausch+Lomb Company
  • Jazz Pharmaceuticals plc
  • QIAGEN Company
  • Alnylam Pharmaceuticals Inc.
  • Sarepta Therapeutics Inc.
  • Dynavax Technologies Corp.
  • Ionis Pharmaceuticals Inc.
  • Akcea Therapeutics Inc.
  • Arrowhead Pharmaceuticals Inc.
  • Dicerna Pharmaceuticals lnc.
  • SomaGenics Inc.
  • Wave Life Sciences Ltd.
  • Exicure Inc.

第32章竞争基准化分析

第 33 章. 竞争对手仪表板

第三十四章 重大併购

第35章 未来前景与潜力分析

第36章附录

简介目录
Product Code: r15191

Oligonucleotide therapy is a comprehensive term encompassing advanced molecular-targeting agents that utilize chemically synthesized oligonucleotides featuring single-stranded DNA (DNA) or RNA (RNA) backbones with inherent selectivity. Oligonucleotides are designed to form base pairs with DNA or RNA strands for various applications, with their most prevalent use being in PCR primers (polymerase chain reaction).

The primary categories of oligonucleotide therapy include antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (AS ONs) are artificial DNA oligomers designed to hybridize with a specific target RNA sequence. They have proven effective in limiting gene expression, modifying precursor messenger RNA splicing, and deactivating microRNAs. This therapeutic approach finds applications in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, among others, and is applied in healthcare facilities and research institutes.

The oligonucleotide therapy market research report is one of a series of new reports from The Business Research Company that provides oligonucleotide therapy market statistics, including oligonucleotide industry global market size, regional shares, competitors with an oligonucleotide market share, detailed oligonucleotide therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oligonucleotide industry. This oligonucleotide therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $4.9 billion in 2023 to $5.61 billion in 2024 at a compound annual growth rate (CAGR) of 14.4%. The expansion in the historical period can be attributed to increased investments in research and development, the introduction of early therapies to the market, advancements in gene editing techniques, initial therapeutic discoveries, and the introduction of RNAi and antisense oligonucleotides.

The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $8.75 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The expansion in the forecast period can be attributed to increased investments in research and development, global market penetration, the expansion of therapeutic areas, strategies for disease modification, and regulatory adaptations. Major trends in the forecast period include personalized therapies, advancements in delivery systems, innovations in RNA interference (RNAi), advancements in antisense oligonucleotides, and the integration of gene editing techniques.

The increase in cancer cases globally is expected to contribute to the oligonucleotide therapy market's growth during the forecast period. For example, as of January 2022, the American Cancer Society projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, averaging around 1,670 fatalities daily. The most prevalent cancer types globally-lung, prostate, bowel, and female breast cancer-constitute 43% of all new cancer cases. Consequently, the surge in global cancer incidence rates is poised to drive the oligonucleotide therapy market's demand in the coming years.

Government initiatives aimed at research and development in healthcare are anticipated to boost the oligonucleotide therapy market's growth. These initiatives involve specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve defined goals, or instigate positive changes in society. Various government bodies are launching healthcare initiatives to support different aspects, including oligonucleotide therapy. In 2022, the UK government, as per the Department of Health and Social Care, committed £260 million (US $270.65 million) in funding to enhance healthcare research and manufacturing. This funding, provided by BEIS and DHSC, aimed to support NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.60 million) was allocated to assist in expanding life sciences manufacturing in the UK.

The oligonucleotide therapy market faced challenges during the forecast period due to the FDA's limited number of drug approvals. In 2022, the National Library of Medicine reported that only 37 new drug entities were approved, marking the lowest number since 2016. This can be attributed to stringent manufacturing standards and high efficacy criteria set by regulatory bodies for therapy approval, leading to prolonged approval timelines and restricting market growth.

Developers and providers in the oligonucleotide therapy market are investing in research and development to redesign therapy approaches. Innovative oligonucleotides enable precision medicine, selectively targeting genes with minimal side effects, and addressing patient-specific sequences causing rare diseases. In April 2023, the FDA approved Qalsody, an antisense oligonucleotide (ASO), for treating ALS associated with the SOD1 gene mutation. Qalsody targets SOD1 mRNA to reduce protein synthesis.

Major companies in the oligonucleotide therapy market are introducing pediatric-focused therapies to drive market revenues. Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4 through 5, showcases advancements in gene-based treatments for genetic diseases, although not specifically an oligonucleotide therapy.

In September 2022, Vanda Pharmaceuticals, a US-based biopharmaceutical company, and OliPass, a South Korea-based biotechnology company, announced a strategic partnership to develop antisense oligonucleotide (ASO) therapeutics. This collaboration aims to jointly develop a series of ASO molecules based on OliPass' proprietary modified peptide nucleic acids, leveraging the strengths of both companies to advance ASO-based precision medicine therapeutics.

Major companies operating in the oligonucleotide therapy market report are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline PLC, Gelead Sciences Inc., BioNTech SE, Moderna Inc., Biogen Inc., Bausch + Lomb Company, Jazz Pharmaceuticals PLC, QIAGEN Company, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals lnc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Hepion Phrmaceuticals lnc., Avidity Biosciences lnc., Miragen Therapeuutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., PCI Biotech Holdings ASA, Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Dynacure S.A., Arcturus Therapeutics Holdings Inc., Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., Editas Medicine Inc., Evox Therapeutics Ltd., ONK Therapeutics Ltd., PepGen Ltd.

North America was the largest region in the oligonucleotide therapy market in 2023. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oligonucleotide Therapy Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oligonucleotide therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oligonucleotide therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oligonucleotide therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Antisense Oligonucleotide; Aptamer; Other Types
  • 2) By Application: Infectious Diseases; Oncology; Neurodegenerative Disorders; Cardiovascular Diseases; Kidney Diseases; Other End-User
  • 3) By End User: Hospitals; Research Institutes
  • Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Gelead Sciences Inc.; BioNTech SE
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oligonucleotide Therapy Market Characteristics

3. Oligonucleotide Therapy Market Trends And Strategies

4. Oligonucleotide Therapy Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Oligonucleotide Therapy Market Size and Growth

  • 5.1. Global Oligonucleotide Therapy Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Oligonucleotide Therapy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Oligonucleotide Therapy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Oligonucleotide Therapy Market Segmentation

  • 6.1. Global Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Antisense Oligonucleotide
  • Aptamer
  • Other Types
  • 6.2. Global Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Infectious Diseases
  • Oncology
  • Neurodegenerative Disorders
  • Cardiovascular Diseases
  • Kidney Diseases
  • Other End-User
  • 6.3. Global Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Research Institutes

7. Oligonucleotide Therapy Market Regional And Country Analysis

  • 7.1. Global Oligonucleotide Therapy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Oligonucleotide Therapy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Oligonucleotide Therapy Market

  • 8.1. Asia-Pacific Oligonucleotide Therapy Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Oligonucleotide Therapy Market

  • 9.1. China Oligonucleotide Therapy Market Overview
  • 9.2. China Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Oligonucleotide Therapy Market

  • 10.1. India Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Oligonucleotide Therapy Market

  • 11.1. Japan Oligonucleotide Therapy Market Overview
  • 11.2. Japan Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Oligonucleotide Therapy Market

  • 12.1. Australia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Oligonucleotide Therapy Market

  • 13.1. Indonesia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Oligonucleotide Therapy Market

  • 14.1. South Korea Oligonucleotide Therapy Market Overview
  • 14.2. South Korea Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Oligonucleotide Therapy Market

  • 15.1. Western Europe Oligonucleotide Therapy Market Overview
  • 15.2. Western Europe Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Oligonucleotide Therapy Market

  • 16.1. UK Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Oligonucleotide Therapy Market

  • 17.1. Germany Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Oligonucleotide Therapy Market

  • 18.1. France Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Oligonucleotide Therapy Market

  • 19.1. Italy Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Oligonucleotide Therapy Market

  • 20.1. Spain Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Oligonucleotide Therapy Market

  • 21.1. Eastern Europe Oligonucleotide Therapy Market Overview
  • 21.2. Eastern Europe Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Oligonucleotide Therapy Market

  • 22.1. Russia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Oligonucleotide Therapy Market

  • 23.1. North America Oligonucleotide Therapy Market Overview
  • 23.2. North America Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Oligonucleotide Therapy Market

  • 24.1. USA Oligonucleotide Therapy Market Overview
  • 24.2. USA Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Oligonucleotide Therapy Market

  • 25.1. Canada Oligonucleotide Therapy Market Overview
  • 25.2. Canada Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Oligonucleotide Therapy Market

  • 26.1. South America Oligonucleotide Therapy Market Overview
  • 26.2. South America Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Oligonucleotide Therapy Market

  • 27.1. Brazil Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Oligonucleotide Therapy Market

  • 28.1. Middle East Oligonucleotide Therapy Market Overview
  • 28.2. Middle East Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Oligonucleotide Therapy Market

  • 29.1. Africa Oligonucleotide Therapy Market Overview
  • 29.2. Africa Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Oligonucleotide Therapy Market Competitive Landscape And Company Profiles

  • 30.1. Oligonucleotide Therapy Market Competitive Landscape
  • 30.2. Oligonucleotide Therapy Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck & Co. Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. GlaxoSmithKline plc
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Gelead Sciences Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. BioNTech SE
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Oligonucleotide Therapy Market Other Major And Innovative Companies

  • 31.1. Moderna Inc.
  • 31.2. Biogen Inc.
  • 31.3. Bausch + Lomb Company
  • 31.4. Jazz Pharmaceuticals plc
  • 31.5. QIAGEN Company
  • 31.6. Alnylam Pharmaceuticals Inc.
  • 31.7. Sarepta Therapeutics Inc.
  • 31.8. Dynavax Technologies Corp.
  • 31.9. Ionis Pharmaceuticals Inc.
  • 31.10. Akcea Therapeutics Inc.
  • 31.11. Arrowhead Pharmaceuticals Inc.
  • 31.12. Dicerna Pharmaceuticals lnc.
  • 31.13. SomaGenics Inc.
  • 31.14. Wave Life Sciences Ltd.
  • 31.15. Exicure Inc.

32. Global Oligonucleotide Therapy Market Competitive Benchmarking

33. Global Oligonucleotide Therapy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Oligonucleotide Therapy Market

35. Oligonucleotide Therapy Market Future Outlook and Potential Analysis

  • 35.1 Oligonucleotide Therapy Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Oligonucleotide Therapy Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Oligonucleotide Therapy Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer